Changes in liver stiffness and steatosis in children after successful treatment with sofosbuvir/velpatasvir: Results of the PANDAA-PED study

Changes in liver stiffness and steatosis in children after successful treatment with sofosbuvir/velpatasvir: Results of the PANDAA-PED study

Saved in:

Bibliographic Details
Main Authors:	Maria Pokorska-Śpiewak, Ewa Talarek, Małgorzata Aniszewska, Magdalena Pluta, Anna Dobrzeniecka, Magdalena Marczyńska, Giuseppe Indolfi
Format:	Article
Language:	English
Published:	Termedia Publishing House 2024-12-01
Series:	Clinical & Experimental Hepatology
Subjects:	liver fibrosis liver stiffness steatosis hepatitis c sofosbuvir/velpatasvir
Online Access:	https://www.termedia.pl/Changes-in-liver-stiffness-and-steatosis-in-children-after-successful-treatment-with-sofosbuvir-velpatasvir-Results-of-the-PANDAA-PED-study,80,55400,1,1.html
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study
by: Jae Hyun Yoon, et al.
Published: (2025-07-01)

Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye
by: Umut Devrim Binay, et al.
Published: (2025-06-01)

Effectiveness and safety of sofosbuvir/velpatasvir in chronic hepatitis C virus infection of Bangladeshi children
by: Salahuddin Mahmud, et al.
Published: (2025-06-01)

Effects of antiviral therapy on reducing the risk of metabolic syndrome in patients with chronic hepatitis C
by: A. F. Novikova, et al.
Published: (2023-07-01)

Liver steatosis in brain death donors
by: D. V. Voronov, et al.
Published: (2021-04-01)

Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan
by: Daisuke Nakamoto, et al.
Published: (2025-04-01)

Evaluation of hepatic steatosis in obese children and adolescents using immune-inflammatory markers and shear wave elastography
by: Akçiçek Mehmet, et al.
Published: (2025-01-01)

Gut microbiota changes and novel markers associated with liver steatosis in obese patients
by: Kh.A. Moskva, et al.
Published: (2024-05-01)

A case report of sofosbuvir induced drug eruption and literature review
by: Anyue Xia, et al.
Published: (2025-01-01)

MOFI-FL, a novel score for detecting hepatic steatosis and predicting cardiometabolic mortality
by: Juan Reyes-Barrera, et al.
Published: (2025-08-01)

Predictors of hepatic steatosis in living liver donors
by: M. G. Minina, et al.
Published: (2022-12-01)

The Efficacy and Safety of Sofosbuvir Containing Regimen in the Treatment of Hcv Infection in Patients with Haemoglobinopathy
by: Nawfal R Hussein
Published: (2017-01-01)

Quantitative ultrasound for steatosis assessment using Hepatoscope®: Confounding technical factors
by: Adrien Besson, et al.
Published: (2024-12-01)

DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR
by: Syed Hassan Murtaza, et al.
Published: (2024-03-01)

Interplatform Agreement Between Liver Steatosis Analysis and Ultrasound-Guided Attenuation Parameter in the Evaluation of Hepatic Steatosis
by: Chen J, et al.
Published: (2025-07-01)

Risk Factors for Liver Steatosis in Obese Children and Adolescents
by: Yu-Cheng Lin, et al.
Published: (2010-06-01)

Efficacy of Sofosbuvir and Ribavirin in Children Presenting with Hepatitis C at Tertiary Care Hospital, Faisalabad
by: Nagina Shahzadi, et al.
Published: (2023-04-01)

Consistency and reliability of ultrasound-derived fat fraction in hepatic steatosis assessment: influence of posture and breathing variations
by: Tingjing You, et al.
Published: (2025-08-01)

Prediction of sofosbuvir response using interleukin-6 serum level and single nucleotide polymorphism of interferon lambda- 4
by: Amal E Saafan, et al.
Published: (2020-01-01)

Evaluation of Patients' Recovery from Hepatitis C Following Antiviral Treatment with Daclatasvir and Sofosbuvir in AL-Baha Region
by: Fahad Alghamdi, et al.
Published: (2024-06-01)

Diagnostic markers of hepatic steatosis in patients with chronic viral hepatitis C
by: V. V. Tsvetkov, et al.
Published: (2023-05-01)

SVR timelines in hepatitis - C irrespective of viral genotype: An Indian perspective
by: Nambaru Vidya Sagar, et al.
Published: (2025-04-01)

The impact of sofosbuvir/ledipasvir on chronic hepatitis C-infected paediatric patients: a Middle East single-centre experience
by: Mohammad Fadhil Ibraheem, et al.
Published: (2023-11-01)

L-Phenylalanine promotes liver steatosis by inhibiting BNIP3-mediated mitophagy
by: Ying Sun, et al.
Published: (2025-06-01)

Association between the NHHR and hepatic steatosis and liver fibrosis: a population-based study
by: Xiaoxian Yang, et al.
Published: (2025-03-01)

Peripheral blood lymphocyte subsets of Chinese adults with liver steatosis
by: Xiaxiao Yan, et al.
Published: (2025-04-01)

Liver steatosis is positively associated with plasminogen activator inhibitor-1 in apparently healthy individuals with overweight and obesity: A FibroScan-Based Cross-Sectional study
by: Giuseppe Lisco, et al.
Published: (2025-04-01)

Relationship of tea consumption with hepatic steatosis and fibrosis: findings from a longitudinal RaNCD cohort
by: Shaimaa A. Qaisar, et al.
Published: (2025-03-01)

Development of hepatic steatosis in normal and veinous livers of overfed female mule ducks
by: S. Trehiou, et al.
Published: (2025-05-01)

Alcohol Abstinence Rescues Hepatic Steatosis and Liver Injury via Improving Metabolic Reprogramming in Chronic Alcohol-Fed Mice
by: Aiwen Pi, et al.
Published: (2021-09-01)

Diagnostic significance of the newest biomarkers of steatosis progression in patients with stable coronary heart disease, combined with nonalcoholic fatty liver disease
by: I. I. Vakalyuk, et al.
Published: (2018-03-01)

Cobalt exposure was associated with the risk of hepatic steatosis and advanced liver fibrosis based on a cross-sectional study from NHANES
by: Ling Zhang, et al.
Published: (2025-03-01)

Prevalence of Liver Steatosis Among Workers in Ouagadougou and Associated Factors: A Cross‐Sectional Study
by: Delphine Napon‐Zongo, et al.
Published: (2024-12-01)

Clopidogrel ameliorates high-fat diet-induced hepatic steatosis in mice through activation of the AMPK signaling pathway and beyond
by: Ting Tai, et al.
Published: (2024-10-01)

Metabolic mechanism of hepatic steatosis affecting production performance of dairy cows during peak lactation
by: LIU Xiaoyi, et al.
Published: (2024-10-01)

Multiparametric ultrasound liver examination in cardiological overweight patients: determining the cause of fibrosis and severity of steatosis
by: D. Yu. Shestakova, et al.
Published: (2025-02-01)

Morphogenesis of pericellular liver fibrosis in patients with chronic viral hepatitis C associated with hepatic steatosis
by: V. A. Tumanskiy, et al.
Published: (2012-08-01)

Liver Stiffness, Not Steatosis, Predicts Mortality in MASLD Patients: An NHANES Analysis
by: Yuting Huang, et al.
Published: (2024-12-01)

Impact of Sofosbuvir/Daclatasvir treatment on glycemic control and lipid profile in diabetic patients with chronic hepatitis C
by: Tamer Fouad, et al.
Published: (2025-07-01)

Time required to achieve optimum viral load suppression with Ravidasvir/sofosbuvir in chronic hepatitis C patients with or without compensated cirrhosis
by: Nor Asiah Muhamad, et al.
Published: (2025-04-01)